Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Global X SuperDividend ETF — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.47B), while Global X SuperDividend ETF trades at $23.65 (market cap $1.18B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 7.2× Global X SuperDividend ETF's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Global X SuperDividend ETF for 49 Days on average.
| HNGE | SDIV | |
|---|---|---|
Market Cap | $8.47B | $1.18B |
Volume | 1,624,526 | 500,093 |
Sector | Health | Broad Market / Factor |
52-Week High | $105.14 | $26.34 |
52-Week Low | $31.17 | $23.16 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $8.09B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
SDIV trades at $23.88, down 0.21% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, with a 66% price decline since inception noted by Seeking Alpha on September 11, 2026. Recent institutional buying includes Ameritas Advisory increasing its position by 92.6% in Q2 2026 per SEC filings.
High dividend yield attracts income investors but comes with significant capital depreciation risks. Media coverage highlights sustainability concerns, while technical indicators suggest near-term consolidation. The outlook remains cautious due to persistent underperformance versus benchmarks and high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
